Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?

doi:10.3748/wjg.v18.i16.1933

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4670)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

401

HTML

3802

Figures (1-4)

248

Tables (1-3)

219

Sum=4670

Apr 28, 2012 (publication date) through Jan 27, 2025

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Apr 28, 2012; 18(16): 1933-1939
Published online Apr 28, 2012. doi: 10.3748/wjg.v18.i16.1933

Table 2 Comparison of the patient characteristics in the two groups prior to hepatic arterial infusion chemotherapy n (%)

	Group A	Group B	Pvalue
Patients	23	19
Age (yr)	66.6 ± 6.9	65.5 ± 7.3	NS (P = 0.635)
Gender
Male/female	20 (87)/3 (13)	15 (79)/4 (21)	NS (P = 0.488)
Etiology of LC
HCV	13 (57)	11 (58)	NS (P = 0.070)
HBV	2 (9)	6 (32)
HCV + HBV	0 (0)	1 (5)
Alcohol	4 (17)	0 (0)
NonB-nonC	4 (17)	1 (5)
Albumin (g/dL)	3.6 ± 0.6	3.5 ± 0.6	NS (P = 0.503)
Total bilirubin (mg/dL)	1.1 ± 0.7	1.3 ± 0.5	NS (P = 0.397)
PT (INR)	1.19 ± 0.13	1.17 ± 0.10	NS (P = 0.607)
AST (U/L)	64 ± 33	79 ± 51	NS (P = 0.256)
ALT (U/L)	47 ± 30	53 ± 38	NS (P = 0.569)
GGT (U/L)	155 ± 169	76 ± 76	NS (P = 0.067)
WBC (/μL)	4600 ± 1400	4400 ± 900	NS (P = 0.431)
Hb (g/dL)	13.1 ± 2.0	12.8 ± 1.0	NS (P = 0.521)
Plt (× 10⁴/μL)	14.3 ± 6.5	12.1 ± 5.8	NS (P = 0.262)
AFP (median, ng/mL)	7550	3116	NS (P = 0.434)
DCP (median, mAU/mL)	12314	3363	NS (P = 0.159)
Child-Pugh
A/B	12 (52)/11 (48)	6 (32)/13 (68)	NS (P = 0.219)
Child-Pugh score	6.8 ± 1.7	7.1 ± 1.4	NS (P = 0.582)
Number of tumor (s)
≤ 5/6-10/> 10	5 (22)/7 (30) /11 (48)	5 (26)/8 (42) /6 (32)	NS (P = 0.515)
Size of the largest tumor (cm)	7.3 ± 5.2	3.8 ± 1.3	P = 0.008
Vessel invasion
presence/absence	12 (52)/11 (48)	7 (37)/12 (63)	NS (P = 0.320)
Clinical stage
I/II/III/IVA	0 (0)/0 (0)/ 11 (48)/12 (52)	0 (0)/0 (0)/ 13 (68)/6 (32)	NS (P = 0.180)
Duration of treatment received prior to HAIC (mo)	16.3 ± 20.7	36.2 ± 21.5	P = 0.004
Previous number of TACE session (s)	0.9 ± 0.6	4.5 ± 1.8	P < 0.0001
HAIC regimens
5-FU, cisplatin	8 (35)	7 (37)	NS (P = 0.923)
5-FU, natural IFN-α	4 (17)	4 (21)
5-FU, PEG-IFN-α2b	11 (48)	8 (42)

HCV: Hepatitis C virus; HBV: Hepatitis B virus; LC: Liver cirrhosis; PT: Prothrombin time; INR: International ratio; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ glutamyl transferase; AFP: α-fetoprotein; WBC: White blood cell; DCP: Des-γ-carboxyprothrombin; HAIC: Hepatic arterial infusion chemotherapy; TACE: Transarterial chemoembolization; 5-FU: 5-fluorouracil; IFN: Interferon; PEG-IFN-α2b: Pegylated interferon-α2b.

Citation: Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A, Saito S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 2012; 18(16): 1933-1939
URL: https://www.wjgnet.com/1007-9327/full/v18/i16/1933.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i16.1933